Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma

Study of the Efficacy of Reinforcing of the Standard Therapy in COVID-19 Patients With Repeated Transfusion of Immune Plasma From COVID-19 Convalescents vs Exclusive Standard Therapy in Hospitalized COVID-19 Patients

The coronavirus disease 2019 (COVID-19) was classified as a pandemic by the World Health Organization (WHO) in March 2020. The SARS-COV-2 virus is easily transmissible and there is currently no approved treatment with effective results. Although the main epidemiological parameters are currently being studied, apparently the speed of contagion, the incidence and the mortality rate in severe cases appear to be high. Therefore, there is an urgent need to find a viable therapeutic option. The present trial is a pilot study with an objective to determine the efficacy of standard treatment reinforced with two repeated doses in two consecutive days of plasma from former convalescent people of the COVID-19 disease already discharged and / or with results in negative COVID-19 screenings, transfused to hospitalized COVID-19 patients.

Inclusion Criteria:

• Ability to understand the HIP and sign the study IC
• male or female =/> 18 years
• Patient hospitalized with a COVID-19 diagnosis by PCR on nasopharyngeal swabs or any other biological sample.
• Presence of respiratory symptoms and / or fever associated with COVID-19, with clinical evolution time for COVID-19 equal to or less than 7 days.
• Presence of pneumonia on chest X-ray and / or SatO2 <94% aa.
• Sequential Organ Failure Assessment (SOFA) score ≤ 6.
• Accept the condition of complying with the procedures established in the protocol.

Exclusion Criteria:

• Patients with a previous history of allergic transfusion reaction.
• Lactating or pregnant women and a positive pregnancy test.
• Patients who have been treated with plasma in the 21 days prior to the screening / baseline visit.
• Patients who are at the time of study, participating in another clinical trial.
• Patients who haven't completed all study procedures.